Press Release: Ovarian Cancer Market Research 2024: Creation of Novel Biomarkers and Genetic Testing Gaining Pace - Global $31.3 Billion Market Forecasts to 2034
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The global ovarian cancer market accounted for USD 3.06 billion in 2023 and is expected to reach at USD 31.31 billion by 2034 with a…
Press Release: Ovarian Cancer Market Research 2024: Creation of Novel Biomarkers and Genetic Testing Gaining Pace - Global $31.3 Billion Market Forecasts to 2034 - Newscast
Fri, 09 May 2025 05:41:00 GMT PMV Pharma ended the first quarter with $165.8 million in cash, cash equivalents, and marketable securities, compared to $183.3 million as of December 31, 2024. Net cash used in operations was $18.3 ...
Thu, 08 May 2025 12:40:08 GMT The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
Thu, 08 May 2025 12:40:00 GMT The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...
Thu, 08 May 2025 12:16:00 GMT Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.
Thu, 08 May 2025 12:16:00 GMT Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
